Persistent lymphopenia after dimethyl fumarate and fingolimod treatment

被引：0
|
作者：
Hernandez, I. [1 ]
Mulero, P. [1 ]
Neri, M. J. [1 ]
Redondo, N. [1 ]
Abad, E. [2 ]
Tellez, N. [1 ]
机构：
[1] Hosp Clin Valladolid, Neurol, Valladolid, Spain
[2] Hosp Clin Valladolid, Pharm, Valladolid, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P775
引用
收藏
页码：644 / 645
页数：2
相关论文
共 50 条
  • [31] Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation
    Zecca, C.
    Antozzi, C. G.
    Clerici, V. Torri
    Ferrazzini, M.
    Mantegazza, R. E.
    Rossi, S.
    Gobbi, C.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (06): : 623 - 625
  • [32] Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
    Kalincik, Tomas
    Havrdova, Eva Kubala
    Horakova, Dana
    Izquierdo, Guillermo
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Grammond, Pierre
    Onofrj, Marco
    Lugaresi, Alessandra
    Ozakbas, Serkan
    Kappos, Ludwig
    Kuhle, Jens
    Terzi, Murat
    Lechner-Scott, Jeannette
    Boz, Cavit
    Grand'Maison, Francois
    Prevost, Julie
    Sola, Patrizia
    Ferraro, Diana
    Granella, Franco
    Trojano, Maria
    Bergamaschi, Roberto
    Pucci, Eugenio
    Turkoglu, Recai
    McCombe, Pamela A.
    Van Pesch, Vincent
    Van Wijmeersch, Bart
    Solaro, Claudio
    Ramo-Tello, Cristina
    Slee, Mark
    Alroughani, Raed
    Yamout, Bassem
    Shaygannejad, Vahid
    Spitaleri, Daniele
    Luis Sanchez-Menoyo, Jose
    Ampapa, Radek
    Hodgkinson, Suzanne
    Karabudak, Rana
    Butler, Ernest
    Vucic, Steve
    Jokubaitis, Vilija
    Spelman, Tim
    Butzkueven, Helmut
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (04): : 458 - 468
  • [33] PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Lehmann-Horn, Klaus
    Penkert, Horst
    Grein, Peter
    Leppmeier, Ulrich
    Teuber-Hanselmann, Sarah
    Hemmer, Bernhard
    Berthele, Achim
    NEUROLOGY, 2016, 87 (04) : 440 - 441
  • [34] Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
    Hou, Jue
    Kim, Nicole
    Cai, Tianrun
    Dahal, Kumar
    Weiner, Howard
    Chitnis, Tanuja
    Cai, Tianxi
    Xia, Zongqi
    JAMA NETWORK OPEN, 2021, 4 (11) : E2134627
  • [35] Dimethyl fumarate/ocrelizumabCytomegalovirus meningitis, urosepsis and lymphopenia: case report
    Reactions Weekly, 2022, 1932 (1) : 242 - 242
  • [36] Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature
    Russo, Cinzia Dello
    Scott, Kathryn Anne
    Pirmohamed, Munir
    PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [37] DELAYED-RELEASE DIMETHYL FUMARATE-ASSOCIATED LYMPHOPENIA
    Chan, Andrew
    Fox, Robert J.
    Bar-Or, Amit
    Chen, Chongshu
    Fam, Sami
    Gold, Ralf
    Hanna, Jerome
    Mehta, Devangi
    Phillips, J. Theodore
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2019, 90 (12): : E53 - E53
  • [38] A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence
    Diebold, Martin
    Altersberger, Valerian
    Decard, Bernhard F.
    Kappos, Ludwig
    Derfuss, Tobias
    Lorscheider, Johannes
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (12) : 1682 - 1685
  • [39] Comparative tolerability and efficacy of dimethyl fumarate and fingolimod in multiple sclerosis
    Cohn, S.
    Bermel, R.
    Hara, C.
    Hersh, C.
    Fox, R. J.
    Cohen, J.
    Ontaneda, D.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 201 - 201
  • [40] Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers
    Vollmer, Brandi
    Ontaneda, Daniel
    Bandyopadhyay, Anasua
    Cohn, Sam
    Nair, Kavita
    Sillau, Stefan
    Bermel, Robert A.
    Corboy, John R.
    Fox, Roberti
    Vollmer, Timothy
    Cohen, Jeffrey A.
    Alvarez, Enrique
    Hersh, Carrie M.
    NEUROLOGY-CLINICAL PRACTICE, 2018, 8 (04) : 292 - 301
12345